Trial Profile

A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms BEATcc
Sponsors Roche

29 Aug 2024 Planned End Date changed from 1 Nov 2024 to 1 Aug 2025.
29 Aug 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Aug 2025.
04 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com